Prediabetes Market - By Drug Class (Biguanides, Thiazolidinediones, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors), Age Group (Children, Adults, Elderly), Distribution Channel (Wholesale, Retail, Online) – Global Forecast (2024 – 2032)

Prediabetes Market - By Drug Class (Biguanides, Thiazolidinediones, GLP-1 Agonists, SGLT2 Inhibitors, DPP-4 Inhibitors), Age Group (Children, Adults, Elderly), Distribution Channel (Wholesale, Retail, Online) – Global Forecast (2024 – 2032)

Prediabetes Market Size

Prediabetes Market size was valued at around USD 198.4 million in 2023 and is estimated to reach over USD 360.6 million by 2032 with a CAGR of 6.9%. Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be classified as type 2 diabetes. It is considered an intermediate stage between normal glucose levels and diabetes. One of the primary catalysts for the market is the rising prevalence of prediabetes worldwide

To get key market trends

  Download Free Sample

Factors such as sedentary lifestyles, unhealthy dietary habits, obesity, and aging populations contribute to the growing prevalence of prediabetes. For instance, in 2021, the Centers for Disease Control and Prevention (CDC) reported that there was a total of 97.6 million adults aged 18 years or older with prediabetes, comprising 38.0% of the adult population in the U.S. Among adults aged 65 years or older, 27.2 million individuals, accounting for 48.8% of this age group, were identified as having prediabetes. Thus, as more people are diagnosed with prediabetes, there is an increasing demand for preventive measures and interventions to manage and potentially reverse this condition.

Pharmaceutical companies are investing in research and development to innovate antidiabetics drug formulations for the management of prediabetes. These innovations include advance pharmaceutical drug delivery which is estimated to reach USD 3.2 trillion by 2032, such as novel drug delivery systems, combination therapies, and medications with improved efficacy and safety profiles. By developing more effective pharmacological interventions for prediabetes, companies aim to address the unmet medical needs of individuals at risk of developing type 2 diabetes and enhance the options available for healthcare providers.
 

What are the growth opportunities in this market?

 Download Free Sample

Prediabetes Market Trends

• There is a growing emphasis on preventive healthcare globally, stimulated by the recognition of the significant burden that chronic diseases such as type 2 diabetes impose on healthcare systems and society as a whole.
• Prediabetes represents a critical stage where interventions can be implemented to prevent or delay the onset of type 2 diabetes and its associated complications. This focus on preventive healthcare encourages investment in prediabetes screening, diagnosis, and management strategies, propelling the growth in the market.

Prediabetes Market Analysis

Learn more about the key segments shaping this market

 Download Free Sample

Based on drug class, the market is segmented into biguanides, thiazolidinediones, glucagon-like peptide-1 agonists (GLP-1), sodium-glucose cotransporter 2 inhibitors (SGLT2), dipeptidyl peptidase-4 inhibitors (DPP-4), and other drug classes. The biguanides segment is estimated to account for USD 254.6 million by the end of 2032.

• Metformin, a commonly prescribed biguanides, effectively lowers blood sugar levels by reducing glucose production in the liver and improving insulin sensitivity. With the escalating prevalence of prediabetes due to factors such as obesity and sedentary lifestyles, there is a growing demand for pharmacological interventions, aligning with clinical guidelines recommending metformin as a first-line treatment.
• Additionally, ongoing research and development efforts aimed at enhancing biguanides medications' efficacy and safety, coupled with their cost-effectiveness compared to other treatments, further bolster their market potential.

Learn more about the key segments shaping this market

 Download Free Sample

Based on age group, the prediabetes market is segmented into children (12-18 years), adults (18-49), and elderly (50+). The adults (18-49) segment held a substantial revenue of USD 92.7 million in 2023.

• The rising prevalence of prediabetes within this demographic, attributed to lifestyle-related risk factors, contributes to increased diagnosis and treatment demand.
• Heightened awareness campaigns and proactive screening initiatives by healthcare providers further amplify detection rates. Additionally, the market benefits from continuous innovation, with pharmaceutical companies developing tailored interventions and digital health solutions for this age group.
• Lifestyle factors such as poor diet and sedentary habits make adults aged 18-49 particularly susceptible, necessitating interventions to manage prediabetes effectively. Improvements in healthcare infrastructure and enhanced access to care also play a crucial role in propelling the market growth by facilitating timely diagnosis and treatment.

Based on distribution channel, the prediabetes market is segmented into wholesalers/distributors, retail chain, online distribution, and other distribution channels. The wholesalers/distributors segment held a substantial revenue of USD 126.8 million in 2023.

• Wholesalers and distributors possess expansive distribution networks, enabling them to reach various healthcare facilities, pharmacies, and retail outlets efficiently.
• Their ability to purchase products in bulk at discounted rates ensures favorable profit margins. Additionally, skilled management of logistics and supply chains ensures timely delivery and continuous availability of prediabetes-related products.
• Strong relationships with manufacturers afford them preferential treatment and access to new innovations, further bolstering their competitive edge.
• Value-added services, compliance with regulatory standards, and the burgeoning market demand for prediabetes solutions all contribute to the segment's notable revenue within the market.

Looking for region specific data?

 Download Free Sample

In 2023, North America held a significant market share of 40.7% in the prediabetes market and is predicted to witness substantial market growth over the analysis timeline.

• North America boasts advanced healthcare infrastructure and robust research and development capabilities, fostering innovation in prediabetes detection, management, and treatment.
• Increasing awareness among healthcare professionals and the general population about the risks associated with prediabetes has led to higher diagnosis rates and proactive management strategies, stimulating the market growth.
• Moreover, the region's growing aging population, coupled with sedentary lifestyles and unhealthy dietary habits, has contributed to a rise in prediabetes prevalence, further fueling market expansion.

Prediabetes Market Share

The prediabetes industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players have a notable presence in the market.

Prediabetes Market Companies

Some of the eminent market participants operating in the prediabetes industry include

• Abbott Laboratories
• AstraZeneca PLC
• CH Boehringer Sohn AG & Co KG
• Eli Lilly and Company
• Glenmark Pharmaceuticals Limited
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Novo Nordisk A/S
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited

Prediabetes Industry News

• In June 2023, Eli Lilly and Company concluded a definitive agreement to acquire Sigilon Therapeutics, Inc., a biopharmaceutical company dedicated to developing functional cures for various acute and chronic illnesses, including diabetes. This acquisition positioned the company with a strategic edge in the market.

The prediabetes market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2021 to 2032 for the following segments

Click here to Buy Section of this Report

Market, By Drug Class

• Biguanides
• Thiazolidinediones
• Glucagon-like peptide-1 agonists (GLP-1)
• Sodium-glucose cotransporter 2 inhibitors (SGLT2)
• Dipeptidyl peptidase-4 inhibitors (DPP-4)
• Other drug classes

Market, By Age Group

• Children (12-18 years)
• Adults (18-49)
• Elderly (50+)

Market, By Distribution Channel

• Wholesalers/distributors
• Retail chain
• Online distribution
• Other distribution channels

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa